Find clinical trials for Acute Myeloid Leukemia (AML) in Indianapolis, IN
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Acute Myeloid Leukemia (AML) trials near Indianapolis, IN, USA:
The main objective of this study is to evaluate the efficacy of venetoclax in combination with azacitidine to improve Overall Survival (OS) in Acute...
Phase 3
Indianapolis, Indiana, United States and 164 other locations
Eligible untreated patients with FLT3 acute myeloid leukemia (AML) between the ages of 18 and 70 will be randomiz...
Phase 2
Indianapolis, Indiana, United States and 43 other locations
in combination with venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults who ar...
Phase 1, Phase 2
Indianapolis, Indiana, United States and 33 other locations
menin-MLL(KMT2A) inhibitor, in patients with relapsed or refractory acute myeloid leukemia (AML) as part of Phase....
Phase 1, Phase 2
Indianapolis, Indiana, United States and 51 other locations
with Gemtuzumab Ozogamicin(GO) in subjects with relapsed/refractory acute myeloid leukemia. Using a standard 3+3 design, s...
Phase 1
Indianapolis, Indiana, United States and 3 other locations
with fludarabine and cytarabine in treating patients with acute myeloid leukemia (AML), myelodysplastic syndrome ...
Phase 1
Indianapolis, Indiana, United States and 12 other locations
myeloid leukemia (AML) in transfusion-dependent participants with low or immediate-1 risk MDS that is relapsed/refractory...
Phase 2, Phase 3
Indianapolis, Indiana, United States and 126 other locations
Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage
Phase III, multicenter, randomized study with two arms (1:1 ratio) enrolling patients with AML relapsed/refractory after 2, 3, or 4 prior in...
Phase 3
Indianapolis, Indiana, United States and 38 other locations
chemotherapy and bone marrow transplantation in newly diagnosed AML subjects with FLT3 mutation. About 510 subjects will be randomized in a ...
Phase 3
Indianapolis, Indiana, United States and 30 other locations
Clinical trials
Research sites
Resources
Legal